

Catia Morelli, PhD

Catia Morelli is Associate Professor in Clinical Pathology at the Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, Italy, and co-founder and member of the board of directors at NanoSiliCal Devices (<https://www.nanosilicaldevices.com/>). In 1998, she graduated in Pharmaceutical Chemistry and Technologies. Right after she spent a 4 years (1999-2003) training period in cancer research at the Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA (USA). During her stay, she was awarded with a “Special Fellowship Award” (2000) from the American-Italian Cancer Foundation (NY, USA) and a “Fellowship Award” (2002) from Cancer Research Foundation of America (Alexandria, VA, USA). Once back in Italy, she specialized in Clinical Pathology (2003) and obtained the PhD in “*Cellular biochemistry and drugs activity in oncology*” (2006). She conducted her post-doc experience in the molecular oncology field, improving her expertise in pre-clinical experimentation at the Department of Pharmacy and Health and Nutritional Sciences at the University of Calabria. Her research interests have mainly been focused on growth factors/steroid hormones cross-talk signaling and mechanisms of resistance to therapy in breast solid tumors and metastasis. Since 2007, she established interdisciplinary collaborations with Prof. Luigi Pasqua and Prof. Antonella Leggio, with whom she founded NanoSiliCal Devices (2014), a Spin-off Company aimed at development and production of anti-cancer strategies based on the use of multifunctional mesoporous silica devices as innovative tools for targeted therapy (<https://orcid.org/0000-0002-9407-0805>)